Biotech | October 27, 2021
Novavax files for approval of its Covid-19 vaccine in the UK
Filing marks first protein-based vaccine submitted to MHRA for authorization
Filing marks first protein-based vaccine submitted to MHRA for authorization
Key takeaways of recent quarter & conference call highlights
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
This strategic collaboration will enable continued innovation in cancer care
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness
The division is expected to grow to over a 100-member strong team by 2022
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
Subscribe To Our Newsletter & Stay Updated
